Pharmacotherapy of functional gastrointestinal disorders;Medikamentöse therapie funktioneller darmbeschwerden

Arzneimitteltherapie

Volumn 26, Issue 6, 2008, Pages 204-210

  Frieling, Thomas ^a  

^a HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

Constipation; Diarrhea; Dyspepsia; Functional gastrointestinal disorders; Meteorism; Pharmacotherapy; Straining; Visceral hypersensitivity

Indexed keywords

CLONIDINE; DROFENINE; LOPERAMIDE; OCTREOTIDE; PROBIOTIC AGENT; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST;

CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; REVIEW;

EID: 77953392940     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. GFK Marktforschung Nürnberg (2006). Die 100 wichtigsten Krankheiten. Woran die Deutschen nach Selbsteinschätzung leiden. Apothekenumschau 1/2006.
2. Icks A, Haastert B, Enck P, Rathmann W, et al. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol 2002;40:177-83.
3. Drossmann DA. Rome III. The functional gastrointestinal disorders. Lawrence, KS, USA: Allen Press, Inc., 2006.
4. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006;130:296-303.
5. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-55.
6. Gwee K-A, Seng Boon Chua A. Functional dyspepsia and irritable bowel syndrome, are they different entities and does it matter? World J Gastroenterol 2006;12:2708-12.
7. Cremonini F, Talley NJ. Review article: the overlap between functional dyspepsia and irritable bowel syndrome - a tale of one or two disorders? Aliment Pharmacol Ther 2004;20(Suppl 7):40-9.
8. North C, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implication for treatment. World J Gastroenterol 2007;13:2020-7.
9. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005;17:325-31.
10. Kuiken SD, Tytgat GN, Boeckxstaens GE. Review article: drags interfering with visceral hypersensitivity for the treatment of functional gastrointestinal disorders - the clinical evidence. Aliment Pharmacol Ther 2005;21:633-51.
11. Gregersen H, Frieling T. Function and dyspepsia: a start of a new friendship. Neurogastroenterol Motil 2004;16:271-3.
12. Veldhuyzen van Zanten S, Flook N, Chiba N. Management of patients with uninvestigated dyspepsia. CMAJ 2001;164:174-5.
13. Riemann JF. Funktionelle Dyspepsie - Gastritis - Ulkuskrankheit. Internist 2006;47:567.
14. Bytzer P, Hansen JP, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-6.
15. Melzer J, Rösch W, Reichling J, Brignoli R, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20:1279-87.
16. Hohenester B, Ruehl A, Kelber O, Schemann M. The herbal preparation STW5 (Iberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004;16:765-73.
17. Frieling T. Functional and inflammatory bowel disorders. Med Klin (Munich) 2005;101(Suppl 1):139-42.
18. Zar S, Benson MJ, Kumar D. Review article: bloating in functional bowel disorders. Aliment Pharmacol Ther 2002;16:1867-76.
19. Wagner H, Allescher HD. Multi-target therapy in functional dyspepsia. Phytomedicine 2006;13(Suppl V):1-130.
20. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myth and misconceptions about chronic constipation. Am J Gastroenterol 2005;100:232-42.
21. Locke GR, Pemberton JH, Phillips SF. American gastroenterological association medical position statement: guidelines on constipation. Gastroenterology 2000;119:1761-78.